BioCentury | Dec 22, 2014
Company News

Teva sales and marketing update

...the calcium channel blocker amlodipine, the angiotensin receptor blocker valsartan and the diuretic hydrochlorothiazide as Exforge HCT...
BioCentury | Jan 4, 2010
Finance

4Q approvals

...to manage neuropathic pain due to postherpetic neuralgia (PHN) Novartis AG (NYSE:NVS; SIX:NOVN) EC approves Exforge HCT...
BioCentury | Oct 26, 2009
Clinical News

Exforge HCT regulatory update

...The European Commission approved an MAA from Novartis AG for Exforge HCT amlodipine/valsartan/hydrochlorothiazide as substitution therapy to...
...U.S for the indication (see BioCentury, May 11). Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Product: Exforge HCT...
BioCentury | Aug 3, 2009
Clinical News

Exforge HCT regulatory update

...EMEA's CHMP issued a positive opinion on an MAA from Novartis for Exforge HCT amlodipine/valsartan/hydrochlorothiazide to treat...
...adults whose blood pressure is adequately controlled on the combination of amlodipine, valsartin and hydrochlorothiazide. Exforge HCT...
...treat hypertension in May (see BioCentury, May 11). Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Product: Exforge HCT...
BioCentury | May 11, 2009
Clinical News

Exforge HCT regulatory update

...FDA approved an NDA from Novartis for Exforge HCT amlodipine/valsartan/hydrochlorothiazide to treat hypertension. Exforge HCT is an oral...
...Exforge amlodipine/valsartan in the U.S. for the indication. Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Product: Exforge HCT...
Items per page:
1 - 5 of 5